JP2005529870A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529870A5
JP2005529870A5 JP2003583402A JP2003583402A JP2005529870A5 JP 2005529870 A5 JP2005529870 A5 JP 2005529870A5 JP 2003583402 A JP2003583402 A JP 2003583402A JP 2003583402 A JP2003583402 A JP 2003583402A JP 2005529870 A5 JP2005529870 A5 JP 2005529870A5
Authority
JP
Japan
Prior art keywords
kda
polymer
molecular weight
range
molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003583402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529870A (ja
JP4514455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/010976 external-priority patent/WO2003086382A1/en
Publication of JP2005529870A publication Critical patent/JP2005529870A/ja
Publication of JP2005529870A5 publication Critical patent/JP2005529870A5/ja
Application granted granted Critical
Publication of JP4514455B2 publication Critical patent/JP4514455B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003583402A 2002-04-11 2003-04-10 Ｔｎｐ−４７０ポリマー複合体及びその使用 Expired - Fee Related JP4514455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37179102P 2002-04-11 2002-04-11
US41470502P 2002-09-30 2002-09-30
PCT/US2003/010976 WO2003086382A1 (en) 2002-04-11 2003-04-10 Tnp-470 polymer conjugates and use thereof

Publications (3)

Publication Number Publication Date
JP2005529870A JP2005529870A (ja) 2005-10-06
JP2005529870A5 true JP2005529870A5 (enExample) 2006-04-13
JP4514455B2 JP4514455B2 (ja) 2010-07-28

Family

ID=29254460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583402A Expired - Fee Related JP4514455B2 (ja) 2002-04-11 2003-04-10 Ｔｎｐ−４７０ポリマー複合体及びその使用

Country Status (7)

Country Link
US (5) US7332523B2 (enExample)
EP (1) EP1494662B1 (enExample)
JP (1) JP4514455B2 (enExample)
AU (2) AU2003230852B2 (enExample)
CA (1) CA2480666C (enExample)
ES (1) ES2398381T3 (enExample)
WO (1) WO2003086382A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100605A1 (en) * 2001-05-15 2003-05-29 Grupp Stephan A. Methods of treating cancer with angiogenesis inhibitors
WO2003086178A2 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
AU2003230852B2 (en) * 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
WO2006084054A2 (en) * 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
BRPI0607688A2 (pt) 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
CN101868180A (zh) 2007-10-09 2010-10-20 圣路易斯华盛顿州立大学 成像粒子
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
WO2009141826A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2009141823A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
CN102105157B (zh) * 2008-05-22 2015-09-30 特拉维夫大学拉莫特有限公司 聚合物、抗血管生成剂和靶向部分的缀合物及其在制备用于治疗骨相关血管生成状况的药物中的用途
CA2768149A1 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
US8715986B2 (en) * 2009-10-29 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides, ligand-targeted multi- stereoisomer peptide polymer conjugates, and uses thereof
AU2010339809B2 (en) 2009-12-17 2016-05-05 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
EP2575887A4 (en) * 2010-05-25 2015-01-14 SynDevRX CONJUGATES OF OPTIMIZED MEDICINES
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) * 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
EP2822598A4 (en) 2012-03-05 2016-04-13 Univ Ramot POLYMERS WITH THEREOF CONJUGATED THERAPEUTIC ACTIVE SUBSTANCES, METHOD FOR THE PREPARATION THEREOF AND USES THEREOF
AU2014250983B2 (en) 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
WO2015004493A1 (en) 2013-07-11 2015-01-15 General Electric Company Grid power factor control system
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
EP3402529A1 (en) 2016-01-11 2018-11-21 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
TWI820061B (zh) 2017-12-06 2023-11-01 美商建南德克公司 用於免疫組織化學的合成對照
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
ATE150750T1 (de) 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
WO1997032868A1 (en) 1996-03-06 1997-09-12 Tsumura & Co. Novel iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
US6225478B1 (en) 1997-03-05 2001-05-01 Tsumura & Co. Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
AU1820400A (en) 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
AU2001274587A1 (en) 2000-06-22 2002-01-02 Takeda Chemical Industries Ltd. Polymer-containing drug composition
ATE552859T1 (de) * 2000-09-13 2012-04-15 Praecis Pharm Inc Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1330447A2 (en) * 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
AU2003230852B2 (en) * 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
WO2003086178A2 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
EP1699812A2 (en) * 2003-12-29 2006-09-13 Praecis Pharmaceuticals Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof

Similar Documents

Publication Publication Date Title
JP2005529870A5 (enExample)
JP2005177500A5 (enExample)
JP2006516528A5 (enExample)
JP2004532847A5 (enExample)
JP2006503588A5 (enExample)
JP2005501957A5 (enExample)
EP1992645A4 (en) NEW LOW-MOLECULAR HYALURONIC ACID AND / OR SALT AND COSMETIC PREPARATION, PHARMACEUTICAL COMPOSITION AND FOOD COMPOSITION THEREWITH
JP2005515404A5 (enExample)
JP2007506705A5 (enExample)
JP2003517386A5 (enExample)
JP2005515295A5 (enExample)
JP2006512466A5 (enExample)
JP2006525972A5 (enExample)
JP2009523791A5 (enExample)
JP2000095900A5 (enExample)
JP2009215399A5 (enExample)
JP2009109594A5 (enExample)
JP2009019158A5 (enExample)
JP2007197689A5 (enExample)
JP2005232412A5 (enExample)
JP2005163046A5 (enExample)
JP2007131679A5 (enExample)
JP2003119343A5 (enExample)
JP2005082661A5 (enExample)
JP2005154579A5 (enExample)